#Fibrosis ILB®, Low Molecular Weight #Dextran Sulfate (LMW-DS) Shows #Anti-Fibrotic Effects in Pre-Clinical Trial | #Fibrotic #diseases are known to affect several vital organs in the body and are a major cause of mortality and morbidity. There has been a little success in treatment of these diseases so far. ILB®, the Low Molecular Weight Dextran Sulfate (LMW-DS) has shown promising results in a pre-clinical trial...

https://www.scientificeuropean.co.uk/medicine/fibrosis-ilb-low-molecular-weight-dextran-sulfate-lmw-ds-shows-anti-fibrotic-effects-in-pre-clinical-trial/